Population Pharmacokinetics-Based Evaluation of Ceftazidime-Avibactam Dosing Regimens in Critically and Non-Critically Ill Patients With Carbapenem-Resistant Klebsiella pneumoniae

Infection and Drug Resistance, Journal Year: 2025, Volume and Issue: Volume 18, P. 941 - 955

Published: Feb. 1, 2025

This study aimed to describe the population pharmacokinetics (PopPK) of ceftazidime-avibactam (CAZ-AVI) in adult patients, and develop optimal dosing regimens for both non-critically ill critically patients by combining different pharmacokinetic/pharmacodynamic (PK/PD) targets. A prospective, single-center involving who were infected with CRKP received CAZ-AVI therapy was conducted. Nonlinear mixed-effect modeling used a PopPK model. The regimen assessed using Monte Carlo simulation. analysis included 91 steady-state concentrations from 45 patients. data modeled one-compartment typical values CAZ AVI clearances 2.96 L/h 3.09 L/h, volumes distribution 17.76 L 18.25 L, respectively. Our showed that creatinine clearance (CrCL) calculated Cockcroft-Gault equation significantly affected CAZ-AVI. simulation optimized varying renal functions, providing detailed supplements instructions. established model proposed reference adjustment based on severity disease functional status.

Language: Английский

Improving pharmacokinetic/pharmacodynamic outcomes of antimicrobial therapy for pneumonia in the ICU

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(18), P. 2347 - 2365

Published: Nov. 26, 2024

Introduction Pneumonia remains a significant global health challenge due to its high prevalence and mortality rate, challenging treatment. This review explores the best strategies optimize antibiotic therapy for pneumonia in critically ill patients, focusing on pharmacokinetics, pharmacodynamics, therapeutic data.

Language: Английский